Results 1 to 10 of about 203 (93)

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

Case Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd, Sabina Custovic, David Byrd, Deanna Ingrassia Miano, Jasdeep Bathla, Antonious Attallah   +5 more
doaj   +1 more source

Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome

Кардиоваскулярная терапия и профилактика, 2023
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov, Yu. F. Glukhov, E. V. T., B. M. Tankhilevich, D. A. Zateyshchikov, T. V. Khlevchuk, I. B. Bondareva   +6 more
doaj   +1 more source

Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]

Xin yixue, 2022
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj   +1 more source

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia

Case Reports in Cardiology, 2020
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj   +1 more source

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

Journal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng, Shichao Zhang, Mingzhou Li, Guozhong Zhang, Wenfeng Feng   +4 more
doaj   +1 more source

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

The Egyptian Heart Journal, 2023
Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian, Babak Bagheri, Jamshid Yazdani Charati, Shahrnaz Khalaghi, Mohammadreza Iranian, Mahsa Mohammadi   +5 more
doaj   +1 more source

There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2021
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy.
Hari Movva, Rani Rabah, Wondwossen Tekle, Alexandros Georgiadis, Laurie Preston, Hari Kotta, Ameer E. Hassan   +6 more
doaj   +1 more source

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian, Hussein Abu Daya, Arka Chatterjee, Firas Al Solaiman, Mark F. Sasse, William S. Fonbah, Raymond W. Workman, Brittany E. Johnson, Sarah E. Carlson, Brigitta C. Brott, Sumanth D. Prabhu, Massoud A. Leesar   +11 more
doaj   +1 more source

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion

BMC Cardiovascular Disorders, 2002
Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj   +1 more source

Eptifibatide-induced acute profound thrombocytopenia in a patient with left main artery plaque rupture complicated by cardiogenic shock and gastrointestinal bleeding

Journal of Clinical and Preventive Cardiology, 2021
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal, William Van Gaal, Francis A Ponnuthurai   +2 more
doaj   +1 more source